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Simple Summary: According to Directive 2010/63/EU, project proposals involving experiments on
animals have to be approved in a harm-benefit-analysis (HBA) that weighs the potential benefits of
the experiment against the harm inflicted on animals. Only if the benefit outweighs the harm, will the
project be approved. However, it is unclear what counts as a valid benefit. In this paper, we analyze
the underlying premises of the HBA and its consequences for the project evaluation process. We come
to the conclusion that knowledge, as such, is considered a low benefit and that only knowledge
applied to benefit society, e.g., new cancer treatment or potent vaccine, etc., is considered to be a
high benefit. However, we demonstrate that benefit of this kind cannot be assessed prospectively
for research proposals due to the inherent uncertainties of research and the difficulty of determining
extra-scientific factors that are crucial for the generation of societal benefit. As a consequence,
we advocate a reevaluation of current project evaluation and propose to develop an alternative model
for project evaluation.
Abstract: Directive 2010/63/EU (henceforth “Directive”) on the protection of animals used for
scientific purposes mandates that every project proposal in EU member states involving procedures
on living non-human vertebrates and cephalopods has to be approved in an review process, including
a harm-benefit-analysis (HBA), to assess “whether the harm to the animals in terms of suffering,
pain and distress is justified by the expected outcome taking into account ethical consideration and
may ultimately benefit human beings, animals or the environment”. Despite the justifying relevance
of “outcome” and “benefit”, it remains unclear how to understand these concepts. However, national
authorities and applicants require a clear understanding of this to carry out a HBA. To analyze the
underlying premises of the HBA and its consequences for the evaluation process, we introduce a
heuristic to analyze the relation between “outcome”, “benefit” and “prospective benefit assessment”.
We then apply the heuristic to all seven legitimate purposes for animal research stated in the Directive,
namely basic research, translational or applied research, product safety, education and training,
protection of the environment, preservation of species and forensic inquiries. As we show, regardless
of which purpose is aimed for, applicants are hard-pressed to demonstrate tangible benefits in a
prospective assessment. In the HBA, this becomes a problem since—as we argue—the only reasonable,
expected and tangible outcome of research can ever be knowledge. The potential long-term benefits
on the basis of gained knowledge are unforeseeable and impossible to predict. Research is bound to
fall short of these proclaimed societal benefits and its credibility will suffer as long as research has to
validate itself through short-term societal benefit. We propose to revise the ethical evaluation based
on the HBA and we think it necessary to develop an alternative model for project evaluation that
focuses on the value of knowledge as a scientific outcome as a necessary but not sufficient condition
for societal benefit.
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1. Introduction
Concerns about animal research are as old as experimentation on animals itself. When it comes
to the use of animals in research, most people seem to share a strong ethical intuition that harm
inflicted on animals needs to be justified. This general ethical concern for animals is also reflected in
Directive 2010/63/EU [1] “on the protection of animals used for scientific purposes”, which had to
be implemented in the legislation of all European member states by 2013. The Directive states that
“animals have an intrinsic value which must be respected. Therefore, animals should always be treated
as sentient creatures and their use in procedures should be restricted to areas, which may ultimately
benefit human or animal health, or the environment.” ([1], recital 12).
In EU member states, animal protection and academic freedom have become two competing,
legally guaranteed principles. The HBA is evidence of the fact that academic freedom can be limited
because of legal responsibilities towards animals. Every research proposal—“project” in the Directive’s
language—entailing procedures on living non-human vertebrates and cephalopods must be approved
by competent national authorities through a project evaluation, one mission of which is “to assess
whether the harm to the animals in terms of suffering, pain and distress is justified by the expected
outcome taking into account ethical consideration and may ultimately benefit human beings, animals
or the environment” ([1], article 38d).
The Directive also reflects the wish for a harmonized, consistent, impartial and transparent ethical
evaluation tool that gauges both the legal as well as the ethical validity of procedures carried out on
animals. Despite the best intentions behind the HBA, we argue that there are several issues with its
specification that still require reflection and clarification [2]. Much has been written about the concept
of harm and harm assessment [1,3–8], but we seem to lack the same level of conceptual and practical
clarity as to the understanding of benefit. Specifically, it is unclear what the relation between outcome
and benefit is or should be. This is crucial, as the entire idea of the HBA depends on these concepts.
What “outcome” and “benefit” are exactly and how they should be “weighed” is in need of clarification
to prevent the HBA from becoming no more than a laudable, albeit vague idea that fails due to its lack
of applicability.
In the following, we argue that the current idea of a prospective benefit assessment portrays a
distorted understanding of the scientific process. It seems to imply a direct causality between project
and societal benefit, thereby misconceptualizing the research process and it might incentivize scientists
to simplify and overstate the possibilities of obtaining societal benefits. In light of that analysis,
we then question what the role of ethical review in the project evaluation process can plausibly be.
Should ethical review be reduced to a semi-mathematical exercise that generates answers regarding
the justifiability of animal testing in a quasi-algorithmic procedure? Or should it provide guidelines as
opposed to specific instructions on how to evaluate the benefit of research involving animals?
This study seeks to analyze the underlying premises of the HBA as outlined in the Directive [1]
and their consequences for the evaluation process. To this end, we introduce a heuristic to analyze
the relations between “outcome”, “benefit” and “prospective benefit assessment”. We then apply
the heuristic to all seven purposes for animal research, which the directive classifies as legitimate:
basic research, translational or applied research, product safety, education and training, protection
of the environment, preservation of species and forensic inquiries. We methodically analyze and
conceptualize the HBA’s semantics as pertains to the benefit dimension set forth in the Directive.
2. A Brief Heuristic on “Justified by the Expected Outcome ( . . . ) and May Ultimately Benefit”
We argue that the key to understanding the relation between outcome and benefit of an experiment
in the HBA lies in one’s reading of the language “is justified by the expected outcome ( . . . ) and may
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ultimately benefit”. Upon closer examination of these inconspicuous words, certain implicit premises
become apparent.
2.1. The Heuristic of “And”
The reader of the Directive’s passage on the HBA will immediately stumble on the question of
whether outcome and benefit refer to different justifying dimensions. The answer to this question
depends on whether “and” directly links outcome and benefit in the passage “is justified by the
expected outcome ( . . . ) and may ultimately benefit”. Following the interpretation that “and” is
understood as a direct link between outcome and benefit, a legitimizing outcome would have to
be argued to have an expected impact on benefits for humans, animals and the environment. In this
reading, either the outcome itself would equate to benefit or the potential consequences of the outcome
would have to allow for benefits of the specified nature. Either way, the justifying factor in the HBA
would be an outcome that is qualified by its potential to benefit humans, animals and the environment.
If “and” does not directly link outcome and benefit, it would suggest that the legitimization of
a procedure through its outcome is independent of the outcome’s benefit to humans, animals or
the environment. However, in this case “and may ultimately benefit human beings, animals or
the environment” would become obsolete and meaningless. Consequently, the only possible and
meaningful understanding of “and” is a strong link between outcome and benefit.
2.2. The Heuristic of “May Ultimately”
As demonstrated above, outcome and benefit cannot be understood independently of each other
in the Directive. We now aim at analyzing the nature of their relation. First, “may” in “may ultimately
benefit” indicates that the outcome ought to have the potential to be of benefit. Second, the word “may”,
especially in conjunction with “ultimately” indicates some time horizon for achieving benefit. Yet,
what would count as timely or late remains entirely unclear. Cynics might even argue that it is logically
impossible to preclude that any given experiment can “ultimately” (in the far unforeseeable future)
yield some kind of benefit for humans, animals or the environment; nobody, one could argue, can say
with certitude that a particular experiment will never—not even in 500 years—contribute to some sort
of benefit. This would imply that projects eo ipso fulfil the criterion that they may ultimately benefit.
Although it is clear that nobody can exclude the possibility that a project “may” benefit someone
someday, the question remains how substantial the expected benefit is to be, and we are left wondering
how such a thing is to be assessed.
The legitimizing power of a procedure’s outcome has been qualified by its expected benefit,
and that benefit has been qualified as pertaining to humans, animals or the environment. According to
recent publications, catalogues of criteria and guiding documents, the justifying power of benefit is
dependent on a) the time frame within which the benefit shall be reached, and b) the probability of
the projected benefit’s realization [8–12]. For instance, the questions “What” is the benefit, “who” will
benefit, “how” will they benefit and importantly “when” will they benefit? are highlighted in an EU guiding
document [13] and referred to in a recent publication by the “American Association for Laboratory
Animal Science” and “European Federation for Laboratory Animal Science Associations” working
group (AALAS-FELASA) [9] as important parameters in assessing potential benefits. Prior to these
recent publications, published work in the field had been arguing along these lines for years. In 1992 for
instance, Porter [5] qualified benefit by its importance for humans and the likelihood of its achievement.
Scharman and Teutsch [10] propose a checklist model that defines expected benefit as the improvement
and/or development of diagnostics and/or therapies, and factors in the likelihood of its realization as
well. Hirt, Maisack and Moritz [12] restrict “benefit” to “benefit to humans with regard to what kind
and what extent of benefit and the likelihood and time frame of realization” (authors’ translation).
The “expert working group on project evaluation and retrospective assessment” suggests a modified
Bateson’s cube [13], an analysis model that dates from a 1986 publication [14] and has served as
an ethical evaluation tool for animal research ever since. The Bateson’s cube is a 3-dimensional
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grid that evaluates the degree of benefit, the amount of harm to the animals and the likelihood of
benefit. Not only is the degree of benefit decisive, but also the likelihood of achieving it. Moreover,
Bout et al. [11] have developed another matrix based on the Bateson cube, which is used for the HBA
in the Netherlands. In their model, the likelihood of the benefit (scientific and/or practical) is more
than just a contributing factor in the weighing process; it is a stand-alone criterion. If the likelihood of
success is too low, the proposal has to be rejected, regardless of its strengths. Again, preference is given
to projects that yield foreseeable benefit. Stafleu et al. [15] proposed a numerical algorithmic model
with a detailed set of formulas for calculating harm and benefits. While the authors do acknowledge
both the difficulty of prospective benefit assessment and the legitimate value of knowledge as an
experimental outcome, only human health interests are capable of getting the maximum score in their
evaluation tool. Interestingly, economic interests are accorded the same legitimizing power as the
generation of knowledge in the Stafleu et al. model.
In this brief overview of relevant published work on the HBA, a pattern emerges in which the
understanding of “benefits” is “foreseeable, expected, societal benefit.” The generation of direct,
societal benefit factors more heavily in the HBA and is prioritized in literature on the evaluation
process, at the expense of procedures whose intended and foreseeable outcome is of no foreseeable,
tangible and immediate benefit to society. In that scheme, generating knowledge (the outcome of basic
research) is typically regarded as a lesser benefit and weighs less on the scales of the HBA.
From this, it follows that knowledge per se as the outcome of a project is only viewed as a
necessary but not sufficient condition to the justification of harm done to the animals. In this dominant
understanding of the terms, only an outcome which is qualified by its potential to generate societal
benefit, as direct benefit to humans, animals or the environment can succeed to legitimize harm and
thus fulfil the legal requirements. Therefore, knowledge, as experimental outcome, is often considered
of little justifying power. It follows that, e.g., severe harm cannot be justified solely on the grounds
of expected gains in knowledge, as would be the objective of basic research [16,17]. As substantiated
above, the prevailing consensus on the HBA evidently locates justifying power not in an expected
outcome, but in expected societal and tangible benefit. Here, it is important to note that it is not only
important that “benefit” may be generated but that “benefit” should, to some degree, be expected.
Our contention is that the wording “and may ultimately” with regard to “outcome” and “benefit”
in the context of the HBA is interpreted in such a way that scientific benefit (knowledge) as an
experimental outcome has no or little intrinsic value and legitimizes harm in procedures only through
its potential to generate societal benefit (i.e., benefit to humans, animals or the environment beyond
knowledge). Furthermore, the HBA prioritizes timely and likely (i.e., time frame and probability of
success), direct, societal benefit over less tangible benefit, particularly knowledge. We would like to
make it clear that we do not claim that knowledge is not a legitimate outcome of animal research
according to the Directive. Nor do we claim, that an intention to generate societal benefit (e.g., health
or environmental benefit) is a “sine qua non” requirement for project approval. Rather we want to
stress that the HBA prioritizes and gives much more “weight” to societal benefits in project evaluation
compared to knowledge and prioritizes potential societal benefits that seem more tangible and more
likely. The main justifying power of a research project’s outcome is strongly linked to expected societal
benefits and thus, gaining knowledge is on the bottom and, e.g., human health on top of the benefit
hierarchy in the HBA. In the following, we will argue that this hierarchy is questionable with regards
to prospective benefit assessment, due to logic, methodological and practical flaws. We argue that
societal benefits of animal research should be assessed retrospectively, but consider it problematic to
assess them prospectively in a HBA.
3. The Heuristic Applied to All Legal Purposes Listed in the Directive
We have established that in an HBA the justifying power of a project depends on whether, or to
what extent, it fulfils the following criteria:
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1. proof that the project may ultimately benefit humans, animals or the environment;
2. prospective qualification of the outcome with regards to its potential and expected benefits;
3. prediction of the likelihood and time frame of achieving the benefit.
To ascertain whether the seven purposes for animal research which the directive classifies as
legitimate meet the above requirements, we now apply the heuristic to all seven legal purposes
specified by the Directive, namely, basic research, translational or applied research, product
safety, education and training, protection of the environment, preservation of species and forensic
inquiries ([1], article 5).
3.1. Basic Research
Basic research is defined as experimental or theoretical research whose primary intent is to add
to or improve knowledge without aiming at any particular foreseeable practical application [18].
The justifying power of basic research depends on the value of knowledge as such, i.e., knowledge
independent of application.
3.1.1. Proof That It May Ultimately Benefit Humans, Animals or the Environment
In 1970, Comroe and Dripps [19] analyzed the impact of basic research on the development of the
10 hitherto most influential medical therapies for pulmonary and cardiac diseases. They were able to
determine that 2500 publications had contributed to the emergence of one of those therapies, 60% of
which was attributable to basic research. A more recent study [20] found that two recently approved
drugs, one for cancer (Ipilimumab) and the other for cystic fibrosis (Ivacaftor), were mainly contingent
on 433 publications over 46 years and 355 publications over 47 years, respectively (this is only counting
the most influential contributions while omitting smaller contributions.). Many of these publications
are again attributable to basic research and these findings paved the way for important innovations,
showing that basic research can meet the criterion of proof that it may ultimately benefit humans, animals
or the environment.
3.1.2. Prospective Qualification of the Outcome with Regards to Its Potential and Expected Benefits
Because basic research seeks to add to the knowledge base and is not conducted for the sake
of any particular practical application [18], most of the studies mentioned above would have been
hard-pressed to identify what societal benefit they might yield. If a practical application were foreseen,
the study would cease to be basic research. Basic research generates knowledge that is a necessary
but not sufficient precondition for the generation of the societal benefit. Basic research is, by nature,
afflicted with an immanent uncertainty about what conclusions it will draw and consequently with
uncertainty as to what benefit can potentially arise from its findings. That makes predicting societal
benefits rather implausible, so basic research fails to meet this requirement.
3.1.3. Prediction of the Likelihood and Timespan of Achieving Benefit
As mentioned, the generation of benefit from research is a non-linear process. The generation of
societal benefits is most often neither intended nor foreseeable.
Furthermore, a prospective assessment of benefits only becomes plausible if the outcome of
the experiment is known beforehand (e.g., one knows whether a hypothesis will be verified and
not falsified). This, however, rests on a logical mistake that neglects the inherent uncertainty in
research: If it was already known whether the hypothesis will be verified or falsified, there would be
no additional knowledge gained from the experiment. Further, it would be illegal to carry out such
research, since it would not result in additional knowledge.
Being unable to foresee benefits, basic research cannot possibly fulfil this criterion, either.
In summary, the outcome of basic research is knowledge as such, which does fulfil the criterion
of proof that it may ultimately benefit humans, animals or the environment. It fails, however, to meet
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the requirements for prospective qualification of the outcome with regards to its potential benefits and
prediction of the likelihood and time frame of achieving benefit. If judgement is to be based upon the criteria
implicit in the Directive, the expected results of basic research can have little justifying power in
prospective assessment.
3.2. Translational or Applied Research
The United States National Institute of health (NIH) [21] defines translational research as “ . . .
the process of applying discoveries generated during research in the laboratory, and in preclinical
studies, to the development of trials and studies in humans...”. Applied research in the medical field,
for instance, seeks to translate aggregate existing findings into medical innovations and advances
(“bench to bedside”) [22]. This category of research is more goal-oriented than basic research, which
means its potential benefits might also appear more tangible at first glance. Knowledge as such is
not only sought, it is sought in light of a hypothesis about a particular application (knowledge as a
means to an end). The Directive allows for the use of animals in applied and translational research
pursuing any of the following goals: “(i) the avoidance, prevention, diagnosis or treatment of disease,
ill-health or other abnormality or their effects in human beings, animals or plants; (ii) the assessment,
detection, regulation or modification of physiological conditions in human beings, animals or plants;
or (iii) the welfare of animals and the improvement of the production conditions for animals reared for
agricultural purposes” ([1], article 5b).
3.2.1. Proof That It May Ultimately Benefit Humans, Animals or the Environment
As shown under point (a), the published findings of basic and applied research have paved
the way for great achievements in medicine [19,20]. Applied and translational research effectively
bridge the gap between basic research and clinical application (“bench to bedside”) and constitute
another important step towards societal benefit. Thus, applied and translational research can fulfil
this criterion.
3.2.2. Prospective Qualification of the Outcome with Regards to Its Potential and Expected Benefits
Since applied and translational research are conducted in light of more practical hypotheses and
their potential benefits appear more tangible than those of basic research at first glance, it is possible to
prospectively qualify the outcome with regards to the nature of its potential benefits, e.g., new cancer
treatment. However, the fact that a benefit can potentially be obtained says nothing about whether
that benefit can actually be expected and, as we have shown in the heuristic, having the potential to
create benefit does not suffice; the decisive factor is that benefits be expected.
The knowledge gained through any experiment is a necessary but not sufficient condition for
the generation of societal benefit, and applied and translational research are afflicted with the very
same uncertainty as basic research. Yet, a prospective assessment of the expected benefits created
by hypothesis-driven research could only be made under the assumption that one already knows
whether a hypothesis will be verified/falsified, i.e., what knowledge will be gained. Without knowing
the outcome, potential benefit cannot be gauged. However, if the outcome were known, the project
would be neither necessary nor legal, since it would not result in additional knowledge. It is inherently
uncertain what, if any, gains in knowledge will be made, which means it is uncertain whether potential
benefits might be realized. This demonstrates that applied and translational research do not meet the
criterion of prospective qualification of the outcome with regards to its potential benefits.
3.2.3. Prediction of the Likelihood and Time Frame of Achieving Benefit
Again, the same uncertainties apply here as in basic research. It is also worth noting that
non-scientific factors outside the responsibility and competence of researchers complicate the issue
of prospective (societal) benefit assessment even further. Consider Susan, an imaginary scientist
whose new cancer drug has just been approved for use. She is now confronted with several problems.
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No pharmaceutical company will produce her drug without financial incentive. Intuitively, one might
argue that a definite medical need will automatically yield a sufficient economic incentive. Furthermore,
while that probably does hold true more often than not, some approved drugs will never make it
to market or are discontinued due to limited market potential [23,24]. Among pharmaceutical flops,
we find Exubera, an insulin inhalant which, although effective, was never able to benefit humans.
It failed financially due to lack of patient compliance: the inhalator was simply too big [24]. In addition,
Orphan diseases present cases in which a definite medical need will not necessarily translate into
sufficient market potential (depending on the country, an “orphan disease” is defined by an incidence
rate of 1 to 8 in 10,000 people [25]).
The approval of new drugs constitutes a certification of their efficacy and safety. After that,
medical professionals and patients still need to be convinced that they should administer or use them,
thereby altering their treatment regimen. Decisions of this nature are not always based solely upon
medical reasoning; other factors (of particular note: lobbying [26,27]) also come into play in the medical
profession. Furthermore, as shown with Exubera, a drug’s efficacy and safety cannot ensure that
it will be comfortable, convenient or pleasant for patients. Misuse and/or practical issues are still
more reasons that even approved medication will not always end up benefiting humans. Duract,
for instance, was a nonsteroidal anti-inflammatory drug that had to be recalled because it caused
kidney failure in patients who took it longer than indicated [28].
All of these non-scientific factors clearly impact the likelihood that expected benefits will
ultimately be obtained. Even though they can make or break the benefit dimension, these factors are
certainly not in researchers’ hands. Altogether, they make predicting the likelihood that, or establishing
a temporal horizon by which point benefits stemming from scientific research will be seen, unrealistic.
Thus, the criterion of prediction of the likelihood and time frame of achieving benefit is not fulfilled.
In summary, also the outcome of applied and translational research is knowledge as a means to
an end (i.e., cancer treatment), which fulfils the criterion of proof that it may ultimately benefit humans,
animals or the environment. It also meets the requirement for prospective qualification of the outcome with
regards to its potential benefits (e.g., cancer drug). However, it fails with regards to whether these benefits
can be expected. It also fails to fulfil the criterion of prediction of the likelihood and time frame of achieving
benefit. If judgement is to be based upon the criteria implicit in the Directive, the expected results of
applied and translational research can have little justifying power in prospective assessment.
3.3. Intermission: Notes on the Distinction between Basic and Applied/Translational Research
At this juncture, it seems fitting to note that we have, in keeping with the Directive’s phrasing,
treated basic research and applied/translational research separately. Both politics and the general
public maintain a sharp distinction between basic and translational/applied research, and there is a
strong bias towards the latter in terms of perceived significance [29]. To a large extent, this probably
stems from a presumption that the more concrete benefit-oriented ultimate goals of applied and
translational research do in fact generate more societal benefit than do the pursuits of basic research.
However, the deeper misconception seems to be that these two branches of research are entirely
different matters and function independently of one another.
The parallels between our discussions of basic research and applied/translational research point
to the groundlessness of any distinction and hierarchization on the basis of societal benefit, as—when it
comes to the generation of societal benefit—there is really no clear line between the two. Both branches
of research primarily add to or improve knowledge and, as the outcome of research in general,
knowledge is a necessary but never sufficient condition for societal benefit. Furthermore, the poor
reproducibility and translational value that is observed in most pre-clinical studies [30–33] shows
that, even though potential societal benefits are more easily identified in applied and translational
research compared to basic research, does not mean they can be predicted with certainty. Based on
this, we question the hierarchy of benefits from knowledge at the bottom to societal benefit on top.
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The low reproducibility and translational value are partly attributed to insufficient scientific
standards. Therefore, an alternative model for project evaluation should be developed that shifts
the focus in project evaluation from societal benefit to maximizing epistemic benefit (i.e., valid
knowledge). To this end, we believe the top priority in project evaluation should be on methodological
soundness and scientific standards to reduce bias and gain reliable results (e.g., by blinding, allocation
concealment, randomization, adequate sample sizes, appropriate statistics) and applying the 3R’s:
“replacement”, “reduction” and in particular “refinement” [34].
3.4. Regulatory Tests
Regulatory tests are mandated by legislation. They may be carried out on animals in pursuit of
any of the goals listed under point (b) in the development, manufacture or testing of the quality,
effectiveness and safety of drugs, foodstuffs and feedstuffs and other substances or products.
The justifying power of these tests is based on the qualification of their outcome (knowledge) with
regards to its direct application (product safety). The intended outcome is not knowledge as such,
but knowledge as a means to an end, i.e., product safety as societal benefit.
3.4.1. Proof That It May Ultimately Benefit Humans, Animals or the Environment
Substances are tested on animal models before being used on target species in an effort to minimize
the risk of unwanted effects. The quality, effectiveness and safety of the tested substances can be of
great importance for human health, so regulatory tests fulfil the criterion that they may ultimately benefit
humans, animals or the environment.
3.4.2. Prospective Qualification of the Outcome with Regards to Its Potential and Expected Benefits
The potential outcome of regulatory testing is knowledge directly applicable in the assurance
of product safety (societal benefit). To that, we would like to add three remarks. First, even though
product safety is a potential ultimate outcome, it remains uncertain whether that outcome can be
expected. The points previously made regarding uncertainty in applied and translational research
apply here as well. Second, a debate over “luxury” or “unnecessary” products resulted in a European
ban on animal testing for cosmetics in 2013 [35], implying that some products are more important
than others. If that is the case, there needs to be a comprehensive hierarchical list of products in order
of “importance” to ensure consistency. Does the safety of a vaccine constitute a greater benefit than
that of a redundant food additive? Or shall we agree to limit testing to “important” products? Then,
there needs to be a comprehensive list of all products that fall under that category, and any exceptions
or conditions which might affect “importance” need to be established in advance. Conversely, let us
imagine that products which have little to add to existing societal benefits, like the 400th sunscreen,
score enough justifying power in an HBA to authorize the use of animals. On the grounds of equal
treatment of equals, few to no projects could be rejected.
Third, what happens if a legal regulation requires a certain testing regime, but the results of an
HBA indicate otherwise?
3.4.3. Prediction of the Likelihood and Time Frame of Achieving Benefit
In regulatory animal testing, the likelihood and time frame of obtaining benefits depend on the
translatability of the knowledge gained through animal models to target species. If translatability
is high, the time frame for creating benefit will be short. If translatability is low, the time frame for
creating benefit becomes difficult to predict. However, translatability has been questioned [36,37] and
in strictly methodological terms, as long as animals are being used as model organisms, there will
always be uncertainty about the translatability of knowledge gained through animal testing to humans,
other animals or the environment. If translatability is uncertain, predicting the likelihood and time
frame of benefit creation becomes equally uncertain. Thus, regulatory tests do not fulfil this criterion.
We do, however, acknowledge that this mainly holds true for substances that have not been tested
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before. Substances that have been tested before and have proven to be safe, have been marketed and
consumed do not suffer from the same uncertainty regarding translatability (e.g., vaccines that are
approved for marketing still undergo batch testing). In this case, the proximity of the animal test to
product safety might allow for a plausible prospective benefit assessment.
In summary, regulatory tests do fulfil the criterion that they may ultimately benefit humans,
animals and the environment. It is also possible to prospectively qualify the outcome with regards to
the nature of its potential benefits, i.e., product safety. The fact that a benefit can potentially be obtained
does not bring certainty about when or whether said benefit can be expected, and the creation of
benefit in product testing ultimately hinges on the translatability from model to target species, a factor
that can vary depending on whether an untested substance or a substance is tested that has already
been tested and found safe (e.g., vaccines batch testing). Thus, depending on the substance tested,
regulatory tests can meet the requirement of prediction of likelihood and time frame of benefit creation.
3.5. Education: Higher Education, or Training for the Acquisition, Maintenance or Improvement of
Vocational Skills
The intended and foreseeable outcome of training is knowledge as a means in terms of a
particular skill.
3.5.1. Proof That It May Ultimately Benefit Humans, Animals or the Environment
Scientists using animals in their research have greatly benefited humans, animals and the
environment many times [19,20,38–40]. Medical innovations, for instance, depend on highly skilled
and trained scientists. Thus, education and training as a necessary condition for the future use of
animals in scientific research fulfils the criterion of proof that it may ultimately benefit humans, animals or
the environment.
3.5.2. Prospective Qualification of the Outcome with Regards to Its Potential and Expected Benefits
Conducting procedures on animals in the context of training to improve skills and techniques is
a necessary condition to ensure, for instance, that researchers and veterinarians are able to perform
surgeries, to guarantee maximum welfare for animals and compliance with the 3Rs. The skill or
knowledge gained is qualified by its potential to yield benefit upon being put into practice. However,
it is unknown whether a trainee will ever actually use the acquired skill in a procedure that might
potentially generate societal benefit. For example, only a fraction of veterinary students trained on
large animals (e.g., horses, cattle) will ever end up working in that field research or in a large animal
clinic. Even if they do, the potential societal benefits of potential future procedures remain unknown.
Nobody can know whether a trainee will use her skills to transplant lungs in pigs or to conjoin the
circulatory systems of two mice, etc. Although possible criteria for benefit in this context can be
identified, uncertainties remain. Is it the number of trained people or the number of instances in which
acquired skills are put into practice? The criterion of prospective qualification of the outcome with regards
to its potential benefits is fulfilled but—on the basis of the reasons given—it can be questioned whether a
benefit besides knowledge can be expected with sufficient probability.
3.5.3. Prediction of the Likelihood and Time Frame of Achieving Benefit
As no potential benefits of potential future procedures can be surmised, it is difficult to assess the
likelihood and time frame of benefit generation, so the criterion of prediction of the likelihood and time
frame of achieving benefit seems difficult to fulfil.
In summary, the outcome of training and education on live animals is knowledge also in the
form of practical skills. This fulfils the criterion that these endeavors may ultimately benefit humans,
animals or the environment. However, it remains implausible in most cases to predict either the nature
of potential benefit besides knowledge or when and how likely it is to be realized. Thus, they fail
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the criterion of prediction of the nature of benefit, the likelihood and the time horizon of realization
of benefit.
3.6. Environmental Protection, Preservation of Species and Forensic Inquiries
Protection of the natural environment in the interests of the health or welfare of human beings
or animals, research aimed at the preservation of species and forensic inquiries all seek to guarantee
and/or improve the quality of human and animal life. The outcome is knowledge as a means of
guaranteeing and/or improving the quality of human and animal life.
3.6.1. Proof That It May Ultimately Benefit Humans, Animals or the Environment
The knowledge gained from these kinds of inquiry and its value as a necessary condition for
guaranteeing and/or improving the health and quality of life of humans and animals mean that these
studies fulfil the criterion that they may ultimately benefit humans, animals or the environment.
3.6.2. Prospective Qualification of the Outcome with Regards to Its Potential and Expected Benefits
Potential benefits resulting from all three of these branches of research clearly revolve around
improving or maintaining the quality of human and animal life. In the specific case of forensic inquiries,
the safety and stability of human society is promoted by solving crimes; potential benefits include
proving the innocence of an erroneously convicted person or proving the guilt of a murderer. In the
preservation of a species, it is the benefit for humans, animals or the environment that arises from
preserving this species. So, all three of these fields fulfil the criterion of prospective qualification of the
outcome with regards to its potential benefits. However, it remains impossible to predict whether these
benefits can be expected.
In the preservation of species, it would be particularly interesting to know whether the degree of
perceived benefit depends on the importance of the species—is the benefit greater when a keystone
species [41] is saved? Or an endangered species? Or a charisma species [41]?
3.6.3. Prediction of the Likelihood and Timespan of Achieving Benefit
Although the goals pursued in these fields are very practical in nature, the same problems
continue to apply, as they apply to research in general. Every inquiry is afflicted with an inherent
uncertainty which makes the likelihood of achievement and a time horizon by which point benefit will
be seen quite unpredictable.
In summary, environmental protection, the preservation of species and forensic inquires fulfil the
criteria that they may ultimately benefit humans, animals or the environment and to prospectively qualify
their outcome with regards to the nature of its potential benefits. However, they cannot fulfil the criterion of
prediction of the likelihood and time frame of achieving benefit.
Based on the application of the heuristic to all seven legal purposes of animal use in research
listed in the Directive, we conclude that it is possible to identify potential societal benefits for the legal
purposes except for basic research which does not have a primarily application-directed goal. However,
we question whether societal benefits can be expected and whether they can be plausibly assessed
prospectively, especially with regards to likelihood and timeframe of their realization. We argued
that the only reasonably expected outcome in animal research for any of the seven legal purposes is
knowledge and we therefore object the hierarchy of proposals based on prospective benefit assessments.
Regulatory tests of known substances as well as some forms of education might represent exceptions
where the proximity of the experiment to application can potentially be close enough to make
prospective benefit assessment plausible. However, even in these exceptional cases, there remains
considerable uncertainty regarding nature, likelihood and timeframe of benefit generation.
Animals 2018, 8, 34 11 of 14
4. Conclusions
Critique of the Focus on Short-Term Benefit
We conclude that the current conception and implementation of the HBA equate “outcome” with
“potential societal benefit”. Projects are qualified by their direct and foreseeable benefits to humans,
animals or the environment. The more tangible a project’s expected benefit seems, and the more
likely and foreseeable (the sooner, the better) the attainment of that benefit appears to be, the greater
the legitimizing power a proposal can gain in an HBA. Yet, the outcome of projects in the areas that
constitute legitimate uses of animals in scientific research as stipulated by the Directive rarely meets
these criteria. What are the underlying reasons for this paradox? We believe it is mainly the product of
a misunderstanding of the scientific process and what can reasonably be expected from good scientific
practice. The notion that one single project, or a few consecutive projects combined create foreseeable,
societal benefit bespeaks an oversimplification of the complex nature of research. It suggests an illusory,
direct and virtually immediate causality between research projects and benefit. We are not arguing
that there is no causality whatsoever between research and benefit; science (biomedical) has repeatedly
benefited humans, animals and the environment greatly [19,20,38–40]. Our point is that the nature of
the relationship between research and societal benefit is neither linear nor immediate. The fact that
many benefits have only been possible because of research that used animals in no way implies that
all such research will bring about societal benefits immediately. As we have argued, the relationship
between a project’s outcome and any benefit derived therefrom is less controllable and less predictable
than implicitly suggested in the literature we reviewed. Made explicit, the prevailing conception of the
HBA applies criteria which cannot be fulfilled due to logical, methodological and non-scientific factors.
The strong bias towards expected societal benefits we identified has already been criticized by
others. Mike Lauer, Deputy Director of extramural research at the National Institute of Health (NIH),
stresses the importance of basic research as a cornerstone of a diverse science portfolio that actively
pursues a thoughtful combination of short-term and long-term goals [42]. Dieter M. Imboden, former
president of the Swiss National Science Foundation, protested that the focus on benefit in an ethical
HBA represents a paradigmatic shift in legislation, which occurred in the absence of debate on the
value of knowledge. He asserts that this is regrettable and fatal ([29], authors’ translation). The shift
that Imboden observes was foreshadowed by the cases of neuroscientists Kevan Martin and Andreas
Kreiter. In 2006, Martin had to stop his work on macaques in Zurich. The reasoning of the verdict
referred to the violation of the animals’ dignity and the lack of foreseeable, tangible short-term societal
benefit [16]. Shortly thereafter, in 2007, the local government of Bremen decided not to renew Kreiter’s
license to work with macaques because it was “too far from applications” [16,43,44].
We contend that prospective project assessment on the basis of expected benefits is a misguided
idea, not on the grounds that expecting benefits is wrong, but because their prospective assessment
is highly uncertain, and prediction of benefits is well-crafted speculation at best. That is exactly
what the HBA in its present form demands from applicants. In this respect, applicants are at risk of
promising too much [45]. Logical, methodological and non-scientific factors can seriously undermine
any prospective benefit assessment and contribute altogether to a high degree of uncertainty as to
how a particular project may ultimately benefit humans, animals and the environment. These factors
radically question the plausibility of the HBA as it currently stands.
We propose to replace the HBA with a “harm-knowledge-analysis” (HKA) for prospective project
evaluation and an analysis of the societal benefits in a retrospective evaluation in the form of systematic
reviews. In the harm-knowledge-analysis, the inflicted harm on animals would be weighed against
and justified by the expected knowledge gain. The importance of the expected knowledge gain
would be qualified by its impact on a given research field or research objective (i.e., important human
interests). On this account of a possible HKA, the main task of competent authorities shifts from benefit
assessment to expected knowledge assessment and the question of whether scientific standards are
met to ensure epistemic gain (i.e., knowledge). Thus, the ethical justification on the project level would
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require two things: First, that a project is carried out in pursuit of significant human interests (identified
on the political level). Second the project design has to meet relevant scientific standards. Whether
the project’s expected outcome is of high or low justificatory power will be identified through the
epistemic gain defined as the expected knowledge contribution to a particular research area. Whether
a particular research area is of sufficient importance should be decided on the political level. Here,
animal research can be debated and justified in light of benefits assessed retrospectively through
systematic reviews. Such systematic reviews would allow for a realistic view of the societal benefits of
animal research. The ways and measures to carry out these reviews and whether these benefits are
assessed every 2, 5, 10 or even 20 years will naturally depend on the research area in question.
The challenges of our proposal are numerous. First, criteria for valid societal benefits have to
be identified on the political level. Second, it needs to be evaluated whether these criteria for valid
societal benefits are met in animal research over time. Third, should a research area fail to produce
the benefits, the question will arise whether this research area justifies sacrificing animals for human
interests. This brings the challenge of how to organize such a public debate and move the ethical
justification of animal research from the project level to the political level.
To conclude, we agree that the use of animals in scientific research ultimately has to be justified
by the benefits it generates for humans, animals and the environment. However, we caution against
legally mandated prospective evaluation that prioritizes short-term societal benefit for the reasons
expressed above. Societal benefits should be evaluated by systematic reviews retrospectively and
cannot be prospectively assessed plausibly in the HBA. Given that prospective benefit assessment in
its present understanding is an exercise in futility, an alternative model for project evaluation that aims
to avoid the pitfalls of its predecessor should be developed.
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